Multi-Omics Based Drug Discovery and Development on October 01-02, 2025 in San Diego, United States

With advances in computing infrastructure and omics technologies within the market, biopharma leaders are increasingly adopting multi-omics within their workflows to accelerate drug discovery and development. In parallel, technology providers are expanding their multi-omics toolkits, with Illumina announcing a new suite of technologies and Element Biosciences raising $277M to develop differentiated products.

The Inaugural Multi-Omics Based Drug Discovery and Development Summit 2025 has been positioned as the premier event for industry leaders to discuss the optimum applications of multi-omics in projects from early discovery to reverse translation, across diverse therapeutic areas including Oncology, Immunology, and Neuroscience.

Join 60+ leaders in Computational Biology, Biomarker Discovery, Translational Research, and Pathology to uncover case studies on the use of harmonized omics technologies to de-risk clinical trials, inform patient stratification, identify biomarkers and novel targets and evaluate therapeutic response. Ensure your company effectively adopts and applies multi-omic technologies to holistically understand disease biology and accelerate the development of precise small molecule and biologic drugs.

URLs:
Tickets: https://go.evvnt.com/3115176-2?pid=10008
Brochure: https://go.evvnt.com/3115176-3?pid=10008

Time: 8:30 AM - 5:00 PM

Prices:

Conference Only Pass - Industry Pricing: USD 2499.00,

Conference Only Pass - Discounted Pricing: USD 2099.00,

Conference Only Pass - Solution and Service Prodiver: USD 3199.00

Speakers: Aarash Bordbar, Co-Founder, Chief Technology Officer, Sinopia Biosciences, Adam Freund, Founder and Chief Executive Officer, Arda Therapeutics, Andrew Parton, Associate Director - Data Science, MultiOmic Health, Anjali Rao, Senior Scientist - Bioinformatics, Gilead Sciences, Bryan Linggi, Senior Director - Translational Medicine, AnaptysBio, Elsa Molina, Director, Single-Cell and Spatial Omics Core, Salk Institute of Biological Studies, Frank Cheng, Director, Bioinformatics, Sonoma Biotherapeutics, James Yurkovich, Chief Technology Officer, Phenome Health, Juan Henao, Senior Scientist, Lipidomics and Metabolomics, BPGBio Inc., Kiana Aran, Associate Professor, UC San Diego, Koichi Hashikawa, Principal Scientist - Computational, Johnson and Johnson, Luke Khoury, Researcher, Northeastern University, Meilan He, Senior Scientist, Poseida Therapeutics, Priyank Patel, Principal Scientist, Boehringer Ingelheim, Sanjeev Ranade, Assistant Professor, Sanford Burnham Prebys, Si Wu, Senior Principal Scientist, Amgen, Todd DeSantis, Vice President, Informatics, Resilient Biotics